[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-444087-105":3,"detail-sidebar-cat-0-en-105":72,"doc-detail-444087-en":122},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":65,"head_meta":67,"extra_data":69,"updated_unix":71},105,"en","impact-of-rapid-molecular-diagnostic-testing-on-outcomes-of-patients-with-vancomycin-resistant-enterococcal-bacteremia","Impact of Rapid Molecular Diagnostic Testing on Outcomes of Patients With Vancomycin-Resistant Enterococcal Bacteremia","","Vancomycin-resistant enterococcal (VRE) bacteremia causes substantial mortality, motivating rapid molecular diagnostic testing (RMDT) to detect enterococci and vancomycin resistance genes directly from positive blood culture broths. A retrospective cohort study (2010–2019) compared preintervention cases without RMDT and postintervention cases after an October 2014 RMDT implementation, focusing on time to active therapy and mortality. RMDT shortened time to effective antimicrobials, while overall 30-day mortality showed no improvement; excluding leukemia patients revealed a transient mortality reduction that did not persist in multivariable analysis.",{"@graph":14,"@context":64},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/impact-of-rapid-molecular-diagnostic-testing-on-outcomes-of-patients-with-vancomycin-resistant-enterococcal-bacteremia/444087/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/impact-of-rapid-molecular-diagnostic-testing-on-outcomes-of-patients-with-vancomycin-resistant-enterococcal-bacteremia/444087.png","ImageObject",300,407,{"name":42,"@type":43},"Bintang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58],{"name":59,"@type":60,"acceptedAnswer":61},"Did RMDT improve mortality outcomes?","Question",{"text":62,"@type":63},"Overall, there was no difference in 30-day mortality between the RMDT and non-RMDT cohorts; a subgroup analysis excluding leukemia suggested decreased mortality, but multivariate analysis did not show persistence of that improvement.","Answer","https://schema.org",{"og:url":32,"og:type":66,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":68,"canonical":32},"index,follow",{"doc_id":70,"site_id":7},444087,1790825496,{"code":4,"msg":73,"data":74},"success",[75,79,83,87,92,97,101,106,111,114,118],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":76,"show_sort_weight":77,"slug":78},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":80,"show_sort_weight":81,"slug":82},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Exam",70,"exam",{"id":88,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},5,"Comic",60,"comic",{"id":93,"doc_module":4,"doc_module_name":25,"category_name":94,"show_sort_weight":95,"slug":96},6,"Technology",50,"technology",{"id":98,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":99,"slug":100},7,40,"healthcare",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},8,"Research & Report",30,"research-report",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},9,"Religion & Spirituality",20,"religion-spirituality",{"id":109,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":109,"slug":113},"World Cup","world-cup",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":115,"slug":117},10,"Lifestyle","lifestyle",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":88,"slug":121},19,"General","general",{"code":4,"msg":73,"data":123},{"doc_id":70,"user_id":124,"nickname":42,"user_avatar":125,"doc_module":4,"category_id":98,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":102,"language":131,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":132,"faqs":133,"seo_title":134,"seo_description":12,"update_tm":135,"read_time":109,"preview_page_count":4},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Open Forum Infectious Diseases  \nMAJOR ARTICLE  \nImpact of Rapid Molecular Diagnostic Testing on Outcomes of Patients With Vancomycin-Resistant Enterococcal Bacteremia  \nMichael R. Hovan,1, Michael J. Burkitt,2 Sierra A. Derti,3 Judith U. Hargrave,4 Angela S. De Cordova,5 Matthew S. Simon,6 Stephen G. Jenkins,6,7 Lars F. Westblade,6,7,8 and Michael J. Satlin6,7,  \n1Department of Medicine, Division of Pulmonary & Critical Care Medicine, NewYork-Presbyterian/Weill Cornell Medicine, New York, New York, USA, 2Pittsburgh Infectious Diseases, LTD. , Pittsburgh, Pennsylvania, USA, 3Department of Medicine, Division of Internal Medicine, Allegheny Health Network, Pittsburgh, Pennsylvania, USA, 4Clinical Microbiology Service, NewYorkPresbyterian/Weill Cornell Medical Center, New York, New York, USA, 5Department of Pharmacy, NewYork-Presbyterian/Weill Cornell Medical Center, New York, New York, USA, 6Department of Medicine, Division of Infectious Diseases, Weill Cornell Medicine, New York, New York, USA, 7Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA, and 8Department of Pediatrics, Weill Cornell Medicine, New York, New York, USA  \nBackground. Vancomycin-resistant enterococci (VRE) bacteremia is associated with substantial mortality. Rapid molecular diagnostic testing (RMDT) that detects enterococci and vancomycin resistance genes from positive blood culture broths may lead to earlier appropriate antimicrobial therapy for VRE bacteremia, which could improve clinical outcomes.  \nMethods. We conducted a retrospective cohort study of patients with VRE bacteremia from 2010 to 2019. RMDT that detects enterococci and vancomycin resistance genes from positive blood cultures was implemented in October 2014. We compared time to active antimicrobial administration, mortality, and other outcomes in patients whose positive blood cultures underwent RMDT (postintervention) and those whose did not (preintervention) .  \nResults. Of 577 eligible patients with VRE bacteremia, 237 (41.1%) had blood cultures that underwent RMDT. The RMDT cohort had shorter median time from culture collection until receipt of active antimicrobial therapy (21 vs 32 hours, P \u003C .001) than the non-RMDT cohort. There was no difference in 30-day mortality (31.6% vs 36.5%, P = .230) . A post hoc subgroup analysis excluding patients with leukemia (who received empiric VRE-active therapy based on Gram stain results) found that RMDT was associated with decreased 30-day mortality: 29.6% versus 40.8%, P = .037. On multivariate analysis, that improvement in 30-day mortality in patients without leukemia did not persist.  \nConclusions. RMDT was associated with decreased time to receipt of active antimicrobial therapy in VRE bacteremia. There was no improvement in mortality associated with the use of RMDT. RMDT for VRE bacteremia may improve time to identification and treatment of VRE bacteremia but does not clearly improve clinical outcomes.  \nInfections due to vancomycin-resistant enterococci (VRE) are associated with significant morbidity and mortality and posea significant public health threat in the United States and globally [ 1] . The US Centers for Disease Control and Prevention (CDC) classifies VRE at a threat level of “serious,” the second highest antimicrobial resistance threat level that the CDC assigns [2, 3] . Vancomycin-resistant enterococci bacteremia has a 28-day mortality rate ranging from 33.7% to 50.5%[4–6], which is 1.8–2.4 times greater than in those with bacteremia due to vancomycin-susceptible Enterococcus spp [7] . VRE  \nReceived 16 June 2025; accepted 01 December 2025; published online 12 December 2025  \nCorrespondence: Michael R. Hovan, MD, Department of Medicine, Division of Pulmonary & Critical Care Medicine, NewYork-Presbyterian/Weill Cornell Medicine, 525 East 68th Street, Box 96, New York, NY 10065 ([mih2036@nyp.org](mih2036@nyp.org)) .  \nOpen Forum Infectious Diseases®  \n© The Author(s) 2025. Published by Oxf","cbCaitBf0vg9MM36","https://ap.wps.com/l/cbCaitBf0vg9MM36","pdf",546960,"English","# Background\n# Methods\n# Results\n# Conclusions","[{\"question\":\"Did RMDT improve mortality outcomes?\",\"answer\":\"Overall, there was no difference in 30-day mortality between the RMDT and non-RMDT cohorts; a subgroup analysis excluding leukemia suggested decreased mortality, but multivariate analysis did not show persistence of that improvement.\"}]","Impact of Rapid Molecular Diagnostic Testing on Outcomes of Patients With Vancomycin-Resistant Enterococcal Bacteremia | PDF",1790706831]